發送短信 : Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

__    __   _    _     _____    _    _     _____   
\ \\ / // | || | ||  /  ___|| | || | ||  / ____|| 
 \ \/ //  | || | || | // __   | || | || / //---`' 
  \  //   | \\_/ || | \\_\ || | \\_/ || \ \\___   
   \//     \____//   \____//   \____//   \_____|| 
    `       `---`     `---`     `---`     `----`